The Patriots are moving on from Jeremiah Pharms Jr., waiving the defensive tackle ahead of Sunday's 53-man roster deadline. It's a move that says everything about how crowded—and how competitive—New England's interior defensive line has become under Mike Vrabel and Eliot Wolf's regime.
Look at the numbers: The Patriots have 13 defensive tackles on their current roster. Thirteen. That's not a depth chart; that's a tryout camp. When you've got Travis Shaw, Leonard Taylor III, Christian Barmore, and Milton Williams all ahead of you on the depth chart, you're fighting for scraps. Pharms Jr., despite his NFL pedigree, couldn't crack the rotation in a way that justified keeping him around as the final cuts loomed. That's the cold math of roster construction.
This isn't a referendum on Pharms Jr. himself—he's had a journey through the league and presumably has the tape to land elsewhere. But it underscores something encouraging about where Vrabel has taken this defensive front. There's legitimate competition. There are bodies who can move inside, who understand gap integrity, who fit a scheme that demands more from the interior line than previous iterations. When you can afford to waive a veteran, it usually means your cupboard isn't bare.
The real question is whether this deep roster construction at DT is by design or necessity. Either way, it signals intent: the Patriots aren't punting on defense while they reshape the offense around Joshua Dobbs and Drake Maye. They're investing in the lines, and that's the right play for a rebuilding team trying to establish an identity that doesn't depend on rookie quarterback heroics.
Pharms Jr. will find a home elsewhere. That's the nature of these deadlines. But his release is less about his value and more about the Patriots' belief that they can compete up front without him.
Based on reporting from Pats Pulpit.